Additional Safety and Exploratory Efficacy Data at 48 and 60 Months from Open-HART, an Open-Label Extension Study of Pridopidine in Huntington DiseaseAndrew McGarry, Michael R. Hayden, Juha‐Matti Savola et al.|Journal of Huntington s Disease|2020Cited by 22
Safety and Exploratory Efficacy at 36 Months in Open-HART, an Open-Label Extension Study of Pridopidine in Huntington’s DiseaseAndrew McGarry, Michael R. Hayden, Victor Abler et al.|Journal of Huntington s Disease|2017Cited by 18